Sterility Indicators Market (2026 - 2033)

Sterility Indicators Market Summary

The global sterility indicators market size was valued at USD 1.3 billion in 2025 and is projected to grow from USD 1.4 billion in 2026 to USD 2.9 billion in 2033, at a CAGR of 10.9% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 50.0% in 2025. Factors such as the increasing emphasis on infection prevention, stringent sterilization regulations, rising surgical volumes, expanding pharmaceutical manufacturing, and growing adoption of sterility assurance practices are driving market growth.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The market is a specialized segment of the healthcare and medical device industry, comprising products used to verify the effectiveness of sterilization processes. These indicators, including biological indicators, chemical indicators, and chemical integrators, help ensure that medical instruments, laboratory equipment, and other critical devices are free of viable microorganisms before use in clinical, pharmaceutical, or research settings.

The industry is witnessing steady growth due to the increasing emphasis on infection prevention and patient safety across healthcare facilities. Growing awareness among healthcare professionals regarding infection control practices has accelerated the adoption of sterile medical devices and stringent sterilization monitoring protocols. In addition, expanding healthcare infrastructure and improving access to medical services in emerging economies are creating significant growth opportunities by increasing demand for sterile medical equipment and reliable sterility-assurance products.

Stringent regulatory requirements further support market expansion. Regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require healthcare facilities and medical device manufacturers to adhere to rigorous sterilization standards. Compliance with these regulations has increased the adoption of sterility indicators for routine monitoring and validation of sterilization processes.

Furthermore, continuous technological advancements have enhanced the performance and usability of sterility indicators. Improvements in biological indicator formulations have increased their sensitivity, specificity, and turnaround time, enabling more accurate detection of sterilization failures and supporting efficient sterilization quality assurance programs.

Analyst Perspective

The industry is driven by increasing emphasis on infection prevention, stringent sterilization regulations, and the expansion of pharmaceutical and medical device production. Rising surgical volumes, growing adoption of biological indicators for reliable sterilization verification, and the shift toward rapid-readout technologies are improving sterilization efficiency across healthcare and life sciences facilities. The expansion of healthcare infrastructure and pharmaceutical manufacturing in emerging economies is creating new growth opportunities. Companies investing in advanced sterility-monitoring solutions, digital documentation, and products compatible with low-temperature sterilization methods are expected to strengthen their market position, as regulatory compliance and patient safety remain key industry priorities.

Type Insights

The biological indicators segment dominated the market, accounting for approximately 65.0% of revenue in 2025, owing to their high reliability in validating sterilization processes in healthcare and pharmaceutical settings. The rapid expansion of the pharmaceutical industry, particularly in biologics and biosimilars manufacturing, has significantly increased the demand for effective sterilization monitoring solutions. In addition, compliance with international standards such as ISO 11138, which specifies requirements for biological indicators, has further accelerated their adoption by healthcare facilities and medical device manufacturers, as these indicators provide a reliable means of demonstrating sterilization efficacy. For instance, in January 2026, Samsung Biologics announced a three-pillar CDMO expansion strategy to increase its biologics manufacturing capacity and broaden its global production capabilities.

The chemical segment is expected to grow at the fastest CAGR during the forecast period. The rise in healthcare-associated infections (HAIs) has led to stricter regulations and standards for sterilization practices. Regulatory bodies such as the FDA and the Centers for Disease Control and Prevention (CDC) emphasize the need for effective sterilization monitoring, which drives demand for reliable chemical indicators. In addition, increased global health initiatives aimed at improving infection control practices contribute to market growth. Organizations worldwide are investing in better sterilization techniques to combat infectious diseases, thus driving demand for chemical indicators.

Technique Insights

The heat sterilization segment accounted for the largest revenue share in 2025. This can be attributed to the widespread adoption of steam and dry heat sterilization for reusable surgical instruments, laboratory equipment, and medical devices due to their proven effectiveness, reliability, and cost-efficiency. The increasing volume of surgical procedures, growing demand for sterile medical products, and heightened focus on infection prevention across healthcare facilities have further supported segment growth. In addition, stringent regulatory requirements for sterilization validation continue to drive the adoption of heat sterilization methods. The segment is expected to maintain its leading position over the forecast period, supported by continuous technological advancements and established regulatory acceptance.

The low-temperature sterilization segment is expected to grow at the fastest CAGR over the forecast period. These techniques, including ethylene oxide sterilization, hydrogen peroxide gas plasma sterilization, and ozone sterilization, are widely used for heat- and moisture-sensitive medical devices that cannot withstand conventional heat sterilization. The growth of this segment can be attributed to technological advancements, increasing use of complex medical devices, and stringent regulatory requirements for effective sterilization in healthcare settings. In addition, healthcare providers are increasingly adopting advanced low-temperature sterilization technologies that improve operational efficiency, reduce processing time, and support compatibility with delicate medical instruments.

End Use Insights

The hospital segment dominated the market, accounting for the largest revenue share in 2025. The high volume of surgical procedures and the increasing complexity of medical interventions have heightened the need for effective sterilization monitoring to prevent healthcare-associated infections (HAIs) and ensure patient safety. As hospitals continue to perform an increasing number of elective and minimally invasive procedures, the demand for sterility indicators to verify sterilization effectiveness has risen accordingly. In addition, regulatory authorities and accreditation bodies have established stringent sterilization guidelines for hospital settings. Sterility indicators play a critical role in helping healthcare facilities comply with these requirements by verifying that reusable surgical instruments and medical devices have been effectively sterilized before use. Compliance with these standards is essential not only for patient safety but also for maintaining accreditation and meeting regulatory requirements.

The pharmaceutical companies segment is projected to experience the fastest CAGR over the forecast period. This growth is primarily driven by increasing pharmaceutical manufacturing activities, stringent sterility requirements for injectable drugs and biologics, and rigorous regulatory oversight. Regulatory authorities such as the U.S. FDA and the European Medicines Agency (EMA) require pharmaceutical manufacturers to maintain validated sterilization processes and sterility assurance throughout production. As a result, the demand for sterility indicators has increased, as they play a critical role in verifying the effectiveness of sterilization processes and ensuring product sterility from manufacturing through distribution. In addition, product contamination can result in costly recalls, production delays, reputational damage, regulatory actions, and potential risks to patient safety, further reinforcing the importance of reliable sterility monitoring. For instance, in May 2026, the U.S. FDA reported that Fagron Sterile Services had voluntarily recalled multiple sterile drug products due to a lack of sterility assurance following identified deficiencies in sterile manufacturing practices. The incident underscores the importance of validated sterility monitoring and effective contamination control in pharmaceutical manufacturing.

Regional Insights

The North America sterility indicators dominated the market, accounting for a revenue share of 50.0%, in 2025. The growing prevalence of hospital-acquired infections (HAIs), which is driving surging demand for advanced medical devices and pharmaceutical technologies, is expected to propel market growth in the coming years. For instance, in July 2025, the U.S. Department of Health and Human Services (HHS) highlighted the implementation of the National Action Plan to Prevent Healthcare-Associated Infections, which established acute care hospital HAI reduction targets for 2024–2028 based on 2022 baseline data.

To learn more about this report, Download Free Sample Report

U.S. Sterility Indicators Market Trends

The sterility indicators market in the U.S. dominated the regional market in 2025. The increasing investment in R&D by pharmaceutical companies, which has enhanced therapeutic solutions and produced reliable products, is one of the key drivers for the market growth. Expanding the country's healthcare infrastructure, including outpatient surgical centers, has increased the adoption of rigorous sterilization protocols.

Europe Sterility Indicators Market Trends

The sterility indicators market in Europe was identified as a lucrative region in 2025. The growth is driven by the increasing emphasis on infection prevention and effective sterilization practices across healthcare facilities, pharmaceutical manufacturing, and medical device production. In addition, the growing geriatric population has led to a higher prevalence of cardiovascular diseases, diabetes, and cancer, contributing to an increase in surgical procedures and supporting the demand for sterility indicators. Furthermore, stringent regulatory requirements for sterilization validation and routine monitoring are encouraging healthcare providers and manufacturers to adopt reliable sterility indicators across their operations.

Asia Pacific Sterility Indicators Market Trends

The sterility indicators market in Asia Pacific is anticipated to grow at the fastest CAGR during the forecast period. The growth is driven by the rising incidence of diseases such as cancer, cardiovascular conditions, diabetes, and other chronic diseases. For instance, in February 2026, Apollo Hospitals announced plans to expand its hospital capacity in response to increased demand for specialty care driven by cancer, cardiovascular diseases, and other complex conditions, alongside continued investment in advanced healthcare infrastructure. In addition, the region's growing economies have increased investment in the healthcare industry, resulting in advanced sterilization technologies and encouraging market growth.

Key Sterility Indicators Companies Insights

Some of the key companies in the sterility indicators market include Getinge, STERIS, 3M, and Liofilchem S.r.l. Vendors in the market are focusing on increasing their customer base to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives, such as mergers and acquisitions, and partnerships with other major companies.

• STERIS focuses on infection prevention and other procedural products and services, primarily serving healthcare, pharmaceutical, and medical device customers. It offers a comprehensive range of sterility assurance products, including biological indicators for steam and vaporized hydrogen peroxide sterilization.

Key Sterility Indicators Companies

The following are the leading companies in the sterility indicators market. These companies collectively hold the largest market share and dictate industry trends:

• Getinge

• STERIS.

• 3M

• Cardinal Health.

• MATACHANA

• Mesa Labs, Inc.

• Andersen Sterilizers.

• PMS Healthcare Technologies.

• Propper Manufacturing Co., Inc.

• Liofilchem S.r.l.

Recent Developments

• In June 2025, Solventum launched the Attest Super Rapid VH₂O₂ Clear Challenge Pack, the first preassembled, transparent test pack that combines biological and chemical indicators for low-temperature sterilization of medical instruments. The solution streamlines sterilization monitoring, reduces manual assembly errors, and supports faster, more reliable sterility assurance across multiple vaporized hydrogen peroxide sterilization systems.

• In April 2024, the MATACHANA introduced an innovative format for integrating chemical indicators. It aims to maximize environmental sustainability in the sterilization industry. MATACHANA has redefined resource management efficiency and has established new sustainability benchmarks in the medical sector.

Sterility Indicators Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global sterility indicators market report based on type, technique, end use, and region:

• Type Outlook (Revenue, USD Billion, 2021 - 2033)

  • Chemical Indicators

    • Class 1

    • Class 2

    • Class 3

    • Class 4

    • Class 5

  • Biological Indicators

    • Spore Ampoules

    • Spore Suspensions

    • Self-contained vials

    • Spore Strips

• Technique Outlook (Revenue, USD Billion, 2021 - 2033)

  • Heat sterilization

  • Low-temperature sterilization

  • Filtration sterilization

  • Radiation sterilization

  • Liquid sterilization

• End Use Outlook (Revenue, USD Billion, 2018 – 2030)

  • Hospitals

  • Pharmaceutical companies

  • Medical device companies

  • Clinical laboratories/ Research centers

  • Others

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait